Reason for Hope's Chief Science Officer, Lynnette A. Averill, Ph.D., and Logan Neitzke-Spruill, Ph.D. introduce a non-neuroreductionist, multilevel framework that distinguishes mechanisms of action from mechanisms of change, highlighting how neuroplasticity, memory updating, relational processes, contextual factors, and meaning-making may interact to support therapeutic change.

This consensus statement reports 20 points of consensus on managing 5 ethical issues related to the upcoming integration of psychedelic medicines into clinical practice and identifies areas for further research and deliberation.